Skip to content
Search

Latest Stories

Further 18 products added to DND list

A further 18 new products have been entered the list of ‘Drugs for which Discount is Not Deducted’ (DND) in Part II of the Drug Tariff on 1 November, following applications made by the PSNC.

This takes the number of products added to the DND list by the Department of Health and Social Care (DHSC) and the NHS Business Services Authority (NHSBSA) in the last 18 months to over 400.


The latest list of products include Aciclovir 200mg/5ml oral suspension sugar free, Acitretin 25mg capsules and Strattera 4mg/1ml oral solution.

The DND list is updated monthly by the DHSC and includes grouped and individual items, the latter being separately listed in Part II of the Drug Tariff. Any items covered by the ‘Group Items’ heading are not listed again individually in Part II.

See here to see a list of all the monthly changes to the DND status of products.

Pharmacists can also check the Actual Medicinal Product (AMP) listing on Dictionary of Medicines and Devices (dm+d) to identify whether a product meets the DND criteria.

The full list of 18 individual items for which the discount deduction scale will no longer apply:

  • Acetylcysteine 2g/10ml solution for infusion ampoules
  • Aciclovir 200mg/5ml oral suspension sugar free
  • Aciclovir 400mg/5ml oral suspension sugar free
  • Acitretin 25mg capsules
  • A-CYS 600mg effervescent tablets
  • Albunorm 5% solution for infusion 100ml bottles
  • Alpro Organic Soya Original milk
  • Alpro Organic Soya Wholebean Unsweetened milk
  • Aprepitant 125mg capsules and Aprepitant 80mg capsules (combination pack)
  • Arachis oil 130ml enema
  • Aspirin 150mg suppositories
  • Atropine 1% eye drops
  • Atropine 3mg/10ml solution for injection pre-filled syringes
  • Emend 125mg and 80mg capsules (combination pack)
  • Emend 125mg oral powder sachets
  • Solian 400 tablets
  • Strattera 4mg/1ml oral solution
  • Zovirax 200mg/5ml oral suspension

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less